Literature DB >> 15163808

Early MR lymphography with gadofluorine M in rabbits.

Bernd Misselwitz1, Johannes Platzek, Hanns-Joachim Weinmann.   

Abstract

PURPOSE: To investigate the dose and time dependency of gadofluorine M for lymph node imaging and the detection of lymph node metastases in an animal model and to compare gadofluorine M with Gadomer (both, Schering, Berlin, Germany) for lymph node enhancement.
MATERIALS AND METHODS: Enhancement of popliteal and iliac lymph nodes was studied in VX2 tumor-bearing rabbits before injection and at 5-120 minutes and 24 hours after intravenous bolus injection of 0.025, 0.05, and 0.1 mmol gadolinium per kilogram of body weight gadofluorine M (six rabbits) or 0.5 mmol/kg Gadomer (eight rabbits). Effects of treatment and time point at enhancement were evaluated with repeated measures analysis of variance. Means were separated with all-pairs comparison with Tukey-Kramer adjustment. After 1.5-T magnetic resonance (MR) imaging, lymph nodes were removed, and prepared sections were stained with hematoxylin-eosin for microscopic examination.
RESULTS: MR images in VX2 tumor-bearing rabbits revealed rapid and strong signal intensity increase in the functional lymph node tissue by 15 minutes after intravenous injection of gadofluorine M. Maximum enhancement of 165%-309% was observed 60-90 minutes after injection (enhancement with 0.05 and 0.1 mmol/kg significantly different from that with 0.025 mmol/kg, P < or =.05). Metastatic tissue showed only slight enhancement at early time points, resulting in high-contrast differentiation between functional and metastatic tissue. Intravenous injection of the blood-pool agent Gadomer induced only short and inhomogeneous lymph node enhancement (enhancement significantly lower [P < or =.05] than that with gadofluorine M).
CONCLUSION: Findings in the study showed that gadofluorine M produces rapid lymph node accumulation. Diagnosis of lymph node metastases was shown with intravenous injection of gadofluorine M with a minimum effective diagnostic dose of 0.025 mmol/kg. Copyright RSNA, 2004

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15163808     DOI: 10.1148/radiol.2313021000

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  11 in total

1.  Long-term assessment of contrast effects of gadofluorine M and gadofluorine P in magnetic resonance imaging of mice.

Authors:  Fugeng Sheng; Yusuke Inoue; Shigeru Kiryu; Makoto Watanabe; Kuni Ohtomo
Journal:  Jpn J Radiol       Date:  2011-12-02       Impact factor: 2.374

2.  Cell labeling with the positive MR contrast agent Gadofluorine M.

Authors:  Tobias D Henning; Olaf Saborowski; Daniel Golovko; Sophie Boddington; Jan S Bauer; Yanjun Fu; Reinhard Meier; Hubertus Pietsch; Barbara Sennino; Donald M McDonald; Heike E Daldrup-Link
Journal:  Eur Radiol       Date:  2007-01-06       Impact factor: 5.315

3.  Assessment of lymph node metastases by contrast-enhanced MR imaging in a head and neck cancer model.

Authors:  Ki Chang Lee; Woo Kyung Moon; Jin Wook Chung; Seung Hong Choi; Nariya Cho; Joo Hee Cha; Eun Hye Lee; Sun Mi Kim; Hoe Suk Kim; Moon Hee Han; Kee Hyun Chang
Journal:  Korean J Radiol       Date:  2007 Jan-Feb       Impact factor: 3.500

Review 4.  Imaging approaches for the study of cell-based cardiac therapies.

Authors:  Joe F Lau; Stasia A Anderson; Eric Adler; Joseph A Frank
Journal:  Nat Rev Cardiol       Date:  2009-12-22       Impact factor: 32.419

Review 5.  Neuroinflammatory imaging biomarkers: relevance to multiple sclerosis and its therapy.

Authors:  Thomas Tourdias; Vincent Dousset
Journal:  Neurotherapeutics       Date:  2013-01       Impact factor: 7.620

Review 6.  Contrast-enhanced MR imaging of lymph nodes in cancer patients.

Authors:  Seung Hong Choi; Woo Kyung Moon
Journal:  Korean J Radiol       Date:  2010-06-21       Impact factor: 3.500

7.  In vivo detection of embryonic stem cell-derived cardiovascular progenitor cells using Cy3-labeled Gadofluorine M in murine myocardium.

Authors:  Eric D Adler; Anne Bystrup; Karen C Briley-Saebo; Venkatesh Mani; Wilson Young; Steven Giovanonne; Perry Altman; Steven J Kattman; Joseph A Frank; Hans J Weinmann; Gordon M Keller; Zahi A Fayad
Journal:  JACC Cardiovasc Imaging       Date:  2009-09

8.  Comparison of gadofluorine-M and Gd-DTPA for noninvasive staging of atherosclerotic plaque stability using MRI.

Authors:  John A Ronald; Yuanxin Chen; Andre J-L Belisle; Amanda M Hamilton; Kem A Rogers; Robert A Hegele; Bernd Misselwitz; Brian K Rutt
Journal:  Circ Cardiovasc Imaging       Date:  2009-03-24       Impact factor: 7.792

9.  Increased neovascularization in advanced lipid-rich atherosclerotic lesions detected by gadofluorine-M-enhanced MRI: implications for plaque vulnerability.

Authors:  Marc Sirol; Pedro R Moreno; K-Raman Purushothaman; Esad Vucic; Vardan Amirbekian; Hanns-Joachim Weinmann; Paul Muntner; Valentin Fuster; Zahi A Fayad
Journal:  Circ Cardiovasc Imaging       Date:  2009-08-17       Impact factor: 7.792

10.  MR imaging features of gadofluorine-labeled matrix-associated stem cell implants in cartilage defects.

Authors:  Hossein Nejadnik; Tobias D Henning; Thuy Do; Elizabeth J Sutton; Frederick Baehner; Andrew Horvai; Barbara Sennino; Donald McDonald; Reinhard Meier; Bernd Misselwitz; Thomas M Link; Heike E Daldrup-Link
Journal:  PLoS One       Date:  2012-12-12       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.